In the correspondence section of this month's journal there is an interesting debate on the role of medical writers in scientific publication. Dr Vallance raises the issue of ‘medical ghostwriting’ and authors’ responsibilities,1 Professors Holz and Meyer2 rightly confirm that they have appropriately acknowledged the contribution of a medical writer to their publication,3 and Gail Flockhart confirms how her company follows current best practice in publishing.4
The role of medical writers in scientific publication can appear to be a controversial issue. Happily there are well-formulated guidelines to assist authors, medical writers, and editors. This ensures that publications that include medical writers are transparent, ethical, and avoid charges of conflict of interest. Useful sources of information include the International Committee of Medical Journal Editors (http://www.icmje.org/ethical_1author.html), Good publication practice for communicating company sponsored medical research: the GPP2 guidelines5 and the Authors Submission Toolkit.6 Following these guidelines increases trust in the process of peer reviewing and publishing of industry sponsored/supported research.
As the Authors Submission Toolkit6 states ‘help from a professional writer can raise reporting standards, improve compliance with guidelines, and elevate overall editorial quality. The World Association of Medical Editors therefore states, ‘Editors should make clear in their journal's information for authors that medical writers can be legitimate contributors.’… If the contributions of a professional medical writer do not meet authorship criteria, these contributions must be disclosed, including the writer's name and any associated third-party organization. The practice of ghostwriting (ie, the unacknowledged use of writing assistance) for medical publications is deemed unacceptable.’
Eye, like many other journals works to these guidelines. Dr Vallance is of course correct in stating that ghostwriting is unacceptable. The article by Professors Holz and Meyers is an example of best practice where all appropriate acknowledgement of authors and contribution was correctly made. Adhering to these guidelines and Eye's instruction to authors ensure proper transparency and best practice in article submissions.
References
Vallance JH . Comment on ‘Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: ranibizumab and bevacizumab’. Eye 2012; 26: 167; doi:10.1038/eye.2011.193.
Meyer CH, Holz FG . Authors' response to a letter to the editor. Eye 2012; 26: 167–168;doi:10.1038/eye.2011.261.
Meyer CH, Holz FG . Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: ranibizumab and bevacizumab. Eye 2011; 25: 661–672.
Flockhart G . Response to Vallance. Eye 2012; 26: 168;doi:10.1038/eye.2011.194.
Graf C, Battisti WP, Bridges D, Bruce-Winkler V, Conaty JM, Ellison JM et al. Good publication practice for communicating company sponsored medical research: the GPP2 guidelines. BMJ 2009; 339: b4330.
Chipperfield L, Citrome L, Clark J, David FS, Enck R, Evangelista M et al. Authors’ Submission Toolkit: a practical guide to getting your research published. Curr Med Res Opin 2010; 26: 1967–1982.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no conflict of interest.
Rights and permissions
About this article
Cite this article
Lotery, A. Authorship and the role of medical writers. Eye 26, 1 (2012). https://doi.org/10.1038/eye.2011.262
Published:
Issue Date:
DOI: https://doi.org/10.1038/eye.2011.262